Literature DB >> 3296670

Insulin and C-peptide secretory responses to glucagon in man: studies on the dose-response relationships.

B Ahrén, A Nobin, B Scherstén.   

Abstract

The present study investigated the insulin and C-peptide secretory responses to glucagon in non-diabetic humans. Glucagon induced a transient increase in plasma insulin and C-peptide concentrations. At the dose level of 0.5 mg, glucagon elicited more efficient responses than at the dose level of 0.25 mg (p less than 0.05). However, the responses were not further potentiated by glucagon at 1.0 mg. Plasma glucose levels did not change during the first 2 min after glucagon injection, when already a marked increase in plasma insulin and C-peptide levels were observed. Thereafter, however, plasma glucose levels increased, to be maximal at 20 min after glucagon injection. Calculations of the minute-to-minute increase of plasma insulin and C-peptide levels revealed that plasma insulin levels increased by 32 +/- 7% of the increase in plasma C-peptide levels during the first 2 min, and by 36 +/- 6% of the increase in plasma C-peptide levels during the 3rd and 4th min after injection; the difference being the liver extraction of insulin. We conclude from this study in man that glucagon stimulates insulin secretion through both direct and indirect effects, that following glucagon injection, approximately 65% of the secreted insulin is extracted by the liver, and that the dose level of 0.5 mg glucagon is the optimal dose level for the stimulation of insulin secretion.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3296670     DOI: 10.1111/j.0954-6820.1987.tb01265.x

Source DB:  PubMed          Journal:  Acta Med Scand        ISSN: 0001-6101


  7 in total

1.  Arginine is preferred to glucagon for stimulation testing of β-cell function.

Authors:  R Paul Robertson; Ralph H Raymond; Douglas S Lee; Roberto A Calle; Atalanta Ghosh; Peter J Savage; Sudha S Shankar; Maria T Vassileva; Gordon C Weir; David A Fryburg
Journal:  Am J Physiol Endocrinol Metab       Date:  2014-08-26       Impact factor: 4.310

2.  Exocrine and endocrine functional reserve in the course of chronic pancreatitis as studied by maximal stimulation tests.

Authors:  G Cavallini; P Bovo; M Zamboni; O Bosello; M Filippini; A Riela; G Brocco; L Rossi; C Pelle; A Chiavenato
Journal:  Dig Dis Sci       Date:  1992-01       Impact factor: 3.199

3.  Nonaqueous, Mini-Dose Glucagon for Treatment of Mild Hypoglycemia in Adults With Type 1 Diabetes: A Dose-Seeking Study.

Authors:  Morey W Haymond; Maria J Redondo; Siripoom McKay; Martin J Cummins; Brett Newswanger; John Kinzell; Steven Prestrelski
Journal:  Diabetes Care       Date:  2016-02-09       Impact factor: 19.112

Review 4.  Minimizing morbidity of hypoglycemia in diabetes: a review of mini-dose glucagon.

Authors:  Stephanie T Chung; Morey W Haymond
Journal:  J Diabetes Sci Technol       Date:  2014-08-26

5.  Acute metabolic effects of clenbuterol in calves.

Authors:  J Luthman; S O Jacobsson
Journal:  Acta Vet Scand       Date:  1993       Impact factor: 1.695

6.  Short-term glucagon stimulation test of C-peptide effect on glucose utilization in patients with type 1 diabetes mellitus.

Authors:  Viliam Mojto; Zuzana Rausova; Jana Chrenova; Ladislav Dedik
Journal:  Med Biol Eng Comput       Date:  2015-11-25       Impact factor: 2.602

7.  Clinical and experimental pancreatic islet transplantation to striated muscle: establishment of a vascular system similar to that in native islets.

Authors:  Gustaf Christoffersson; Johanna Henriksnäs; Lars Johansson; Charlotte Rolny; Håkan Ahlström; José Caballero-Corbalan; Ralf Segersvärd; Johan Permert; Olle Korsgren; Per-Ola Carlsson; Mia Phillipson
Journal:  Diabetes       Date:  2010-07-22       Impact factor: 9.461

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.